Thursday, April 28, 2022 8:26:44 AM
PINPOINT THE PAIN
NOCISCAN – The first, evidence-supported, SaaS platform to leverage MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine.
NOCISCAN
Complete the diagnostic picture
Conventional imaging (lumbar MRI) for Chronic Lower Back Pain offers important structural information but struggles to identify the actual source of pain.
NOCISCAN complements lumbar MRI with critical pain biomarker data.
Noninvasive MRS scan done in conventional MRI
Disc pain information without painful, subjective provocative discography
Know the source of the pain
Objective analysis of pain biomarkers, individualized to each patient
Clear, easy-to-intepret NOCI+/NOCI- scores for each disc- see where the pain is today and highlight discs to watch in the future
When used with other diagnostic tools, NOCISCAN provides critical insights into the source of the patient’s lower back pain
Clarity to optimize treatment decisions
When used with other available data, NOCISCAN helps physicians personalize each treatment and surgical plan with individualized NOCI+ / NOCI- scores and pain biomarker data.
https://aclarion.com/
Recent ACON News
- Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit • GlobeNewswire Inc. • 10/10/2024 11:00:00 AM
- Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes • GlobeNewswire Inc. • 09/27/2024 10:57:00 AM
- PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology • GlobeNewswire Inc. • 09/13/2024 12:30:00 PM
- Aclarion Provides Corporate Update on Nociscan AI Technology Milestones • GlobeNewswire Inc. • 09/12/2024 10:57:00 AM
- Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial • GlobeNewswire Inc. • 09/10/2024 10:57:00 AM
- Aclarion Added to PRISM Emerging Medical Devices Index • GlobeNewswire Inc. • 09/06/2024 03:27:33 PM
- Aclarion Launches Surgeon Partnership to Apply Nociscan’s AI Technology to Personal Injury and Workers Compensation Market • GlobeNewswire Inc. • 09/05/2024 10:57:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2024 08:01:26 PM
- Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey • GlobeNewswire Inc. • 08/29/2024 10:57:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/26/2024 08:02:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 08:58:12 PM
- Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan’s AI Generated Biomarker Data Changes Surgical Treatment Plans • GlobeNewswire Inc. • 08/21/2024 11:57:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:56:50 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/16/2024 08:01:01 PM
- Aclarion to Present at August 20th Virtual Investor Summit Microcap Event • GlobeNewswire Inc. • 08/15/2024 01:48:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 07:34:17 PM
- Aclarion Announces First Commercial Agreement in Michigan • GlobeNewswire Inc. • 08/14/2024 12:08:00 PM
- Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK • GlobeNewswire Inc. • 08/13/2024 01:07:00 PM
- Form 253G3 - • Edgar (US Regulatory) • 08/13/2024 01:05:23 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 08/13/2024 11:56:18 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 08:02:13 PM
- Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK • GlobeNewswire Inc. • 07/09/2024 11:00:00 AM
- Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK • GlobeNewswire Inc. • 06/26/2024 12:30:00 PM
- Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London • GlobeNewswire Inc. • 06/25/2024 12:30:00 PM
- Aclarion’s Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain • GlobeNewswire Inc. • 04/25/2024 01:14:37 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM